INFINITEVISION

AI-POWERED STRATEGIC PLANNING SOLUTION

The Problem

Inefficient process and missed opportunities for our Patients

01

Low Success Rate of development*

Data related to pharma development processes: 82% of failure rate with approx 2B $ invested per compounding and 6 to 9 years needed to bring a new product on the market.
Slow, inefficient and very expensive.

02

Lack of a fast, actionable and affordable tool

Methodologies to assess new healthcare projects not always leverage quantitative methods and big data. Decision-making processes suffer inaccuracy and bias.

03

Bridging the Commercialization Gap for Emerging Biotech Players*

Emerging biotech companies are increasingly leading pharmaceutical innovation, yet they often lack the commercialization experience necessary for successful drug launches. This gap underscores the critical need for strategic analysis and consulting to navigate market complexities and effectively compete with established players.

*Drug Discovery Today: Volume 29, Issue 11, November 2024, 104160; Acta Pharm Sin B . 2022 Feb 11;12(7):3049–3062; McKinsey and Company, Nov 2024; Deloitte Report, February 2023; DCAT Insights, February 2022 report

FutureInsite®, our automated predictive algorithm developed by healthcare experts for healthcare innovators!

Data-Driven

Our **AI-powered platform FutureInsite, validated with more than 200 projects,** analyze vast datasets to identify patterns and trends, providing valuable **unbiased** insights for informed decision- making.

Fast & Actionable

FutureInsite provides results within 48 hours in an easy to read report based on **6 main indicators**. It provides clear actions to move to market and insights and upgrades to make even better the innovation described.

Personalized

Our AI-powered report is **tailored on individual needs**, enhancing customer satisfaction and driving engagement.

How it Works...

01 Project Description

Using different sources with an easy and user-friendly data intake, the project description is used to set up FutureInsite, allowing identifying the main **Query Vectors**

02 Data retrieving anda data validation

Based on the query vectors, data are retrieved by our multichannel databases. Data are **validated** and ranked based on relevance and opportunity to contribute to project assessment

03 Data Interpretation and PoS

Data are then combined and quantified to generate our 6 main indicators describing the project. Innovation, Market & Investment, Quality & Regulatory, User Need, Cost of Scale-up and Sustainability. Each indicator is quantified with a value between 0 and 100%. The 6 indicators are then combined to generate our First Level Indicator the **PoS** (Probability of Success) of the project to enter the market and sustainably gain market shares.

04 Project Upgrades and Report Out

Data are used to identify opportunities for project upgrades as new features, new markets, new pocket of users. A customized and digital report is then generated. The report is accessible in a security mode in layers, based on needs; from a strategic executive view to a full detail description per each indicator and source.

How we add value to our Partner

01

Profitability

Our tool is designed for sustained profitability, streamlines resource allocation, prioritizes and increases revenue streams and proposes solutions for efficient scaling-up.

02

Risk Management and Decision Making

Our solutions are easily adoptable within the organization and support decision making and risk mitigation based on multichannel market specific, scientific data.

03

ROI

A fast project profiling tool accelerates decision-making, reducing the risk of mistakes, shortens time-to-market, projecting volumes based on data, enabling a quicker return on investment (ROI) in competitive industries like healthcare

Competitive Advantage

01 **Industry- Specific Models**

We develop custom models tailored to the specific healthcare industry, ensuring optimal performance and problem-solving based on our extensive experience in pharma.

02 **Optimization with a Patient Centric Approach**

Our models learn and evolve over time, constantly adapting to new data and improving accuracy of results mainly focusing on what is really needed for patients. Our Databases are constantly improved with special focus on Patient Real Need data interpretation

03 **Scalability**

Our solutions can handle massive datasets and complex workflows, seamlessly scaling with your business needs.

Vast and Untapped Market Opportunity

Innovators & Start Up

80%+ of NMEs (New Molecular Entities) in pharma are identified and developed by Small Emerging companies, Spin-off, single Innovators. They need strategic support to transform ideas and preliminary data in market opportunities, identified the proper partner to scale-up

CDMO

Our solution has been proven to be useful and accurate for the CDMO market as well, where information coming from Client need sanity check before resources and capacity allocation and new investment decision-making.

Venture Capital

Due to data-drive and industry specificity principles at the base of FutureInsite, Healthcare VC and Investors can leverage our report for projects prioritization and investment decision making. Where timing is crucial and several opportunities are in the radar, be the first makes the difference!

Current Portfolio

65%

23%

12%

Data Validation for Smarter CDMO Operations

FutureInsite: Turning Raw Data into Reliable Decisions

Objective:
Support the CDMO in performing a sanity check of project volume data provided by their partner, enabling more accurate, data-driven decision-making and optimized resource allocation.

Challenge:
The CDMO faced uncertainty in the reliability of the partner's data, risking inefficient resource planning and potential capacity issues.

Solution:
Using FutureInsite, InfiniteVision's advanced data intelligence platform, we:
1. *Integrated & Analyzed Data*: Seamlessly processed and validated over 1.2M data points from the partner's project volumes.
2. Provided Actionable Recommendations Including Projected Volumes: Delivered a comprehensive, visually driven report in just 10 business days.

Quantified Value Added:
- Time Saved: Reduced data validation effort by 40%, saving over 120 hours of internal team time.
- Cost Avoided: Prevented potential resource misallocation costs estimated at €480,000 annual (approx 2 weeks capacity free-up as per Client evaluation)

Benefits:
- Enhanced confidence in partner data for strategic decisions.
- Improved allocation of resources, avoiding under/over-utilization.
- Increased operational efficiency, supporting sustainable growth.

Boosting Innovation for a Pharma Startup

FutureInsite: From Bright Ideas to Market-Ready Innovations

Objective:

Support a pharma startup in evaluating the potential of their innovative idea, developing a robust go-to-market (GTM) roadmap, and identifying opportunities to enhance the innovation further

Challenge:

The startup faced uncertainty about the goodness and uniqueness of their idea in the context of evolving market trends and competitive landscapes. They needed a reliable, data-driven validation to assess their innovation's potential and guide strategic decisions, minimizing the risk of misalignment with market needs

Solution:

Using FutureInsite, InfiniteVision's advanced data intelligence platform, we:

1. *Validated Idea Feasibility:* Conducted a detailed comparative analysis against 10 competitors and aligned the idea with 5 key market trends
2. *Discovered & Suggested Enhancements*: Identified 2 key upgrades to the project, enhancing its innovation potential and expanding its market applicability
3. *Designed a GTM Roadmap*: Developed a 12-month action plan detailing critical milestones in R&D, regulatory approvals, and market entry strategies.

Quantified Value Added:

- Time Saved: Accelerated roadmap development by 50%, saving over 3 months of planning effort
- Competitive Edge: Enhanced product differentiation, increasing projected market potential by 20%. (based on Client qualitative information provided)

Empowering Venture Capital with Data-Driven Pharma Investments

FutureInsite: Your Strategic Edge in Pharma Investment Decisions

Objective:
Assist a Venture Capital (VC) firm specializing in the pharmaceutical sector to evaluate and select the most promising pharma innovators, ensuring well-informed, high-impact investment decisions.

Challenge:
The VC faced difficulties in assessing the true innovation potential of a target pharma innovator. The VC was relying on fragmented data and subjective evaluations. This increased the risk of suboptimal investments and inefficient technical due diligence.

Solution:
Using FutureInsite, InfiniteVision's data intelligence platform, we:
1. *Conducted Comprehensive Assessments*: Analyzed the target with 6 key performance metrics
2. *Delivered Actionable Insights*: Quantifying the technical potential of the innovator based on equipment, capabilities, market trends and current projects pipeline,
3. *Streamlined M&A Technical Visits*: Collaborated with the VC during due diligence, reducing the evaluation timeline by providing pre-validated data and structured visit specific protocol.

Quantified Value Added:
1. *Time Saved:* Reduced evaluation and due diligence process by 30%, saving over 200 hours across internal and external teams.
2. *Strategic ROI Boost:* Enabled better investment alignment, increasing projected returns by 10-15% over initial expectations (*preliminary assumption and calculation*)

Our Trusted Partnerships: Empowering Industry Leaders Across the Pharma Ecosystem

Franco Negron

ADVISOR

CEO Simtra Biopharma

CEO and Board of Director ApiJect

Giuseppe Poli

TESTIMONIAL

Emeritus Professor of General Pathology |
University of Turin - President and CEO |
Panoxyvir

CLIENT TESTIMONIAL

Infinite Vision®

★★★★★

"Gynica's stakeholders were impressed with the detailed and insightful report provided by FutureInsite about our company and technology.
The report provided our team with valuable insights that helped focus our R&D and business efforts. It highlighted potential product upgrades leveraging latest scientific advancements that could further differentiate us, while the market analysis also assisted in strategic planning.
I would highly recommend FutureInsite's analysis capabilities to any organization looking to objectively evaluate their technology and refine strategy. The report supported us with aligning our leadership team and investors on priorities to drive growth and value-creation for Gynica. Mirko and the team were professional and adaptive to the company's needs"

Yotam HOD - CEO Gynica

CLIENT TESTIMONIAL

"It is impressive how the algorithm manages a thorough analysis of the business, proposing specific improvements on both technical and business aspects.
This analysis helped us on one hand to confirm some choices and on the other hand to consider interesting new perspectives.
I recommend FutureInsite's analysis to any company, especially early-stage startup, who can use this objective feedback to adjust and improve business strategy."

Angela Sorriento – Co-founder and *CEO MyEcho*

Infinite Vision®

★★★★★

Team and Expertise: Seasoned Founders and Talented Engineers


Experienced Leadership

Our team consists of seasoned founders specialized in pharma operations , strategy development and deployment and pharma finance with a proven track record of success in multinational organizations.

Talented Engineers

Our engineers are highly skilled and passionate about AI and cyber security driving innovation and delivering cutting-edge solutions.

Contacts

InfiniteVision: We Empowering Pharma Innovation with Data-Driven Precision

Website

www.infinitevision.it

Emails

m.gabriele@infinitevision.it

Address

Via Monti 13
04100 Latina
Italy

Cell phone

0039 328 6.84395